The reduced cost of genetic sequencing—from $2.7 billion for the Human Genome Project in 1990 to less than $300 today, and potentially less than $100 in the near future—allows for much more extensive screening of trial participants and targeting of interventions.
The reduced cost of genetic sequencing—from $2.7 billion for the Human Genome Project in 1990 to less than $300 today, and potentially less than $100 in the near future—allows for much more extensive screening of trial participants and targeting of interventions. This has enabled the development of personalized treatment plans and targeted therapies, which are more effective than less-specific therapies because they focus on a patient’s genetic and molecular makeup.